Although D-JNKI1 has not progressed as a clinical cancer treatment, its JNK-dependent otoprotective effects (reviewed in [57]) have prompted several preclinical studies and Phase II/III clinical trials evaluating its efficacy as a treatment for acute hearing loss [58,59]. This evidence concerns the gene MAPK8 and cancer.